HTG Taps Pete Clemens as SVP of Commercial Operations.
HEALTH AND BEAUTY CLOSE-UP-12 September 2008-HTG Taps Pete Clemens as SVP of Commercial Operations(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com HTG, provider of the quantitative Nuclease Protection Assay (qNPA) system and service partner for the life sciences industry, announced the appointment of Pete Clemens to Senior Vice President of...

HTG Inks Collaboration Pact with Harvard Catalyst Laboratory.
HEALTH AND BEAUTY CLOSE-UP-4 December 2008-HTG Inks Collaboration Pact with Harvard Catalyst Laboratory(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com HTG, Inc., a provider of the quantitative Nuclease Protection Assay (qNPA) system and service partner for the life sciences industry, has announced a collaboration agreement with researchers at Harvard Catalyst...

Genome Therapeutics to Present at Informed Investors Beltway Genomics Stocks Forum.
WALTHAM, Mass., May 17 /PRNewswire/ -- Genome Therapeutics Corporation (Nasdaq: GENE), a genomics-based drug discovery company, is scheduled to update investors about the corporate overview, programs and strategy this weekend at the Informed Investors Beltway Genomics Stocks Forum. Date: Saturday, May 19, 2001 ...

DECODE INITIATES PHASE IIA CLINICAL TRIAL FOR DG031.
deCODE genetics (Nasdaq:DCGN), Reykjavik, Iceland, has initiated its ten-week, information-rich Phase IIa clinical trial of DG031, its developmental compound for the prevention of heart attack. The trial is designed to examine the effect of various doses of DG031 on biomarkers such as C-reactive protein (CRP) and myeloperoxidase and on...

Isis Pharmaceuticals' GeneTrove Division Introduces Human Gene Function Database.
Only Antisense Technology-based Database That Will Contain Information on 10,000 Human Genes to Broadly Enhance and Expedite Industry's Drug Discovery Efforts CARLSBAD, Calif., Aug. 9 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIP) announced today that its GeneTrove(TM) division has introduced the...

Immusol, Inc. and Chugai Biopharmaceuticals, Inc. Announce Functional Genomics Alliance.
SAN DIEGO, Feb. 28 /PRNewswire/ -- Immusol, Inc., a privately-held biotechnology company, and Chugai Biopharmaceuticals, Inc. (CBI), a wholly owned subsidiary of Chugai Pharmaceutical Co. Ltd., today announced that they have entered into a Functional Genomics collaboration for drug discovery. In the collaboration, Immusol's proprietary gene inactivation...

Healthcare Technologies Reports First Quarter Results.
Glycodata Achieving Investor Objectives; Savyon Integration of GamidaGen Completed; New Strategic Program Launched ASHDOD, Israel, May 30 /PRNewswire/ -- Healthcare Technologies, Ltd. (Nasdaq: HCTL), today announced unaudited results for the first quarter ended March 31, 2001. Revenues for the...

Genome Therapeutics Announces Extension of Osteoporosis Genomics Alliance With Wyeth-Ayerst.
WALTHAM, Mass., July 16 /PRNewswire/ -- Genome Therapeutics Corp. (Nasdaq: GENE) announced today the extension of a genomics-based research collaboration to develop novel therapeutics for the prevention and treatment of osteoporosis with Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products Corporation (NYSE: AHP). This alliance, which...

Millennium Issued Broad Patent for ACE2 Gene Which Holds Potential For Targeted Disease Management.
- Synergy of Genomics and Biology Continue to Validate Industry's Leading Technology Platform - CAMBRIDGE, Mass., Feb. 27 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that it has received a key United States patent related to the ACE2 gene. The award,...

deCODE and Roche Announce Major Progress in Turning Their Genomic Discoveries In Schizophrenia and PAOD into Novel Drugs and Diagnostics.
REYKJAVIK, Iceland, and BASEL, Switzerland, Feb. 14 /PRNewswire/ -- deCODE genetics (Nasdaq: DCGN; Easdaq) and Roche announced today a breakthrough in their gene and drug discovery collaboration. New targets identified through analysis of genes which deCODE researchers have linked to two common diseases -- schizophrenia and peripheral...